Company / EPS (Diluted)
Haemonetics EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$2.24
FY2025
5-year range
$0.84 / $2.29
FY2021-FY2025
Trend
+166.7%
vs FY2024
Sector context
#53 of 159
Health Care
What the data says
At $2.24, Haemonetics's eps (diluted) ranks #53 of 159 in the Health Care sector. EPS (Diluted) has fluctuated over the past 10 years, ranging from $-1.09 in FY2018 to $2.29 in FY2023.
Based on SEC 10-K filings.
2.24 in FY2025 with a 5-year CAGR of +7.6%.
Declined from $2.29 to $2.24 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- +0.0%
- 5-Year CAGR
- +7.6%
- 10-Year CAGR
- -
Sector benchmark
#53 of 159 in Health CareTop 33% of 159This company $2.24 Sector average $1.66
▼
+35.3% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 166.7% year-over-year.
- Ranks #53 out of 159 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2023.
- Lowest eps (diluted) in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.24 | +166.7% |
| FY2024 | $0.84 | -63.3% |
| FY2023 | $2.29 | +2.2% |
| FY2022 | $2.24 | +166.7% |
| FY2021 | $0.84 | -45.8% |
| FY2020 | $1.55 | +4.7% |
| FY2019 | $1.48 | +235.8% |
| FY2018 | -$1.09 | -440.6% |
| FY2017 | $0.32 | -52.2% |
| FY2016 | $0.67 | -9.5% |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026